Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) [Phase 1]

View source ↗

Summary

Phase 1 study of NTLA-2001 in hereditary transthyretin amyloidosis with polyneuropathy and transthyretin amyloid cardiomyopathy has completed, evaluating safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin Amyloidosis with Polyneuropathy
• Transthyretin Amyloid Cardiomyopathy
• Wild-type Transthyretin Amyloidosis

Drugs mentioned

• NTLA-2001

Snippet

Sponsor: Intellia Therapeutics | Conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Phase 1 | Status: COMPLETED